普拉替尼治疗伴有RET融合突变的局部晚期或转移性非小细胞肺癌的真实世界疗效和安全性分析

Real-word clinical outcomes and safety analysis of pratinib in treatment of locally advanced or metastatic non-small cell lung cancer with RET fusion mutations

  • 摘要:
    背景 我国非小细胞肺癌(non-small cell lung cancer,NSCLC)患者转染重排(rearranged during transfection,RET)基因融合发生率为1.4% ~ 2.5%,普拉替尼(Pralsetinib)是国内第一个获批上市的高选择性RET抑制剂,疗效显著,但其应用缺乏真实世界的数据验证。
    目的 探讨特异性抑制剂普拉替尼治疗伴有RET基因阳性(RET+)的NSCLC的真实世界疗效和安全性。
    方法 本研究回顾性分析了39例2017年3月 — 2022年10月在解放军总医院接受普拉替尼治疗的RET基因阳性的局部晚期或转移性NSCLC患者的临床资料。分析普拉替尼应用于一线、二线及以上治疗的客观缓解率(objective response rate,ORR)、疾病控制率(disease control rate,DCR)、无进展生存期(progression-free survival,PFS)、至治疗失败时间(time to treatment failure,TTF)和药物安全性。
    结果 在39例纳入的研究对象中,女性24例(61.5%),中位年龄59(范围:34 ~ 81)岁,26例(66.7%)为一线治疗,13例(33.3%)为二线及以上治疗,13例(33.3%)患者在用药时已有颅内转移瘤。普拉替尼一线治疗的患者,DCR为88.5%,ORR为50.0%,中位TTF为11.7个月,中位PFS为11.7个月。二线及以上治疗的患者,DCR为76.9%,ORR为23.1%,中位TTF为8.2个月,中位PFS为9.0个月。13例伴有颅脑转移的患者,颅内DCR为84.6%,ORR为46.2%。32例(82.1%)出现治疗相关不良反应,主要为血红蛋白减少(13例,33.3%)和中性粒细胞计数减少(12例,30.8%)。5例发生感染性肺炎,为3 ~ 4级不良反应。无治疗相关不良反应而引起的死亡。
    结论 特异性抑制剂普拉替尼在局部晚期或转移性RET+ NSCLC的治疗中表现出了良好的临床疗效和持久反应,特别是对颅内病变有一定的控制作用,并且安全性良好,但需要重视和识别与普拉替尼相关的肺炎。

     

    Abstract:
    Background The incidence of RET gene fusion translocation in non-small cell lung cancer (NSCLC) patients in China ranges from 1.4% to 2.5%, and pralsetinib is the first high-selective RET inhibitor approved for marketing in China, with significant efficacy. However, its application still lacks real-world data validation.
    Objective To investigate the real-world effectiveness and safety profile of pralsetinib, a specific inhibitor, in the management of non-small cell lung cancer (NSCLC) with RET gene alterations.
    Methods Clinical data from 39 patients with locally advanced or metastatic NSCLC who tested positive for RET fusion and received pralsetinib treatment in Chinese PLA General Hospital from March 2017 to October 2022 were retrospectively analyzed. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), time to treatment failure (TTF), and drug safety evaluations for first-line, second-line, and subsequent pralsetinib treatments were analyzed.
    Results Among the 39 enrolled patients, there were 24 female patients (61.5%) with a median age of 59 (range: 34-81) years. First-line treatment was administered to 26 cases (66.7%), while second-line or subsequent treatments were given to 13 cases (33.3%). At treatment initiation, intracranial metastases were found in 13 patients (33.3%). In patients receiving pralsetinib as first-line therapy, the DCR was 88.5%, the ORR was 50.0%, and both median TTF and PFS were recorded as 11.7 months. For those undergoing second-line or later treatments, the DCR was 76.9%, ORR was 23.1%, with median TTF of 8.2 months and median PFS of 9.0 months. Among the 13 patients with intracranial metastases, the DCR was 84.6%, while the ORR reached 46.2%. Treatment-related adverse reactions were observed in 32 cases (82.1%), with decreased hemoglobin levels being the most prevalent side effect (13 cases; 33.3%). Other adverse reactions included reduced neutrophil count in 12 cases (30.8%), elevated AST levels in 11 cases (28.2%), increased blood pressure in 10 cases (25.6%), raised ALT levels in 10 cases (25%), and diminished lymphocyte count in 9 cases (23%). Notably, 5 patients experienced grade 3/4 infectious pneumonia, but no treatment-related deaths occurred.
    Conclusion Pralsetinib has demonstrated robust clinical efficacy and sustained response in the treatment of locally advanced or metastatic RET fusion-positive NSCLC. Notably, it exhibits notable control over intracranial lesions and maintains excellent safety profile. However, vigilance is required for the identification of pralsetinib-associated pneumonia.

     

/

返回文章
返回